1. Medtech Insight
  2. >>Business

Dexcom Eyes US FDA Clearance For 15-Day CGM, But Insurance Coverage Remains Uncertain

Upgrade could boost Dexcom’s competitive positioning against Abbott’s Libre 3 Plus.

 
• By Shubham Singh

Tempering expectations on the immediate market impact for the upgraded continuous glucose monitor, Dexcom notes insurance coverage and pump integrations will take time to finalize.

The new device is expected to enhance patient experience by extending wear time beyond its current 10-day G7 sensor.
Key Takeaways
  • Dexcom expects to launch its 15-day G7 sensor in the second half of 2025, pending US FDA approval. The company is prioritizing insurance coverage and pump integration before a full rollout. 

      Dexcom is gearing up to launch its 15-day sensor in the second half of this year, pending authorization from the US Food and Drug Association. However, questions remain about the level of insurance coverage the new product will receive, especially in comparison to competitors like Abbott’s FreeStyle Libre 3 Plus, which also offers a 15-day wear period.

      More from Business

      Roche Eyes 2026 FDA Nod After CE Mark For pTau181 Test To Boost Global Alzheimer’s Diagnosis

       
      • By Shubham Singh

      The Elecsys pTau181 test, which requires only a blood sample, provides a less invasive alternative to cerebral spinal fluid procedures. A negative result could rule out Alzheimer’s and help patients avoid further testing with CSF or PET scans.

      FTC Blocks Edwards Lifesciences’ Merger With JenaValve

       
      • By Elizabeth Orr

      The FTC is suing to block Edwards Lifesciences' purchase of JenaValve, citing concerns that it would reduce competition and innovation in the heart valve market and negatively impact patient access to vital treatments for aortic regurgitation. Edwards disagrees with the decision.

      HistoSonics Sells Majority Stake To Investor Syndicate In Deal Valued At $2.25Bn

       
      • By Marion Webb

      HistoSonics’ CEO Michael Blue describes the deal as a win-win for all stakeholders and plans to use the money to expand clinical indications, as well as the global reach, for its Edison system.

      PathAI Talks PCCPs: ‘Accelerated Software Updates, Saves Time And Money’

       
      • By Natasha Barrow

      The US FDA has authorized around 107 devices with Predetermined Change Control Plans in place, with PathAI's AISight Dx digital pathology image management system one of the latest. Medtech Insight talks to Eric Walk, chief medical officer, to find out about the process and its benefits.

      More from Policy & Regulation

      Swiss Medtech To Battle ‘Arbitrary’ 39% US Tariff

       
      • By Ashley Yeo

      In return for building a successful US export business, Switzerland has been handed a 39% tariff effective immediately by the Trump administration. Diplomatic channels have been reopened to undo the tariff. Meanwhile, the medtech industry is looking to develop OUS markets for Swiss exporters.

      Injuries And Deaths Linked To Boston Scientific Cardiac Devices. Company Responds

       
      • By Brian Bossetta

      The US FDA issued a pair of early alerts on Wednesday warning customers about serious adverse events associated with two Boston Scientific cardiac devices. Both alerts include numerous reports of injuries and deaths and are part of the FDA’s ongoing pilot to enhance its recall process.

      PathAI Talks PCCPs: ‘Accelerated Software Updates, Saves Time And Money’

       
      • By Natasha Barrow

      The US FDA has authorized around 107 devices with Predetermined Change Control Plans in place, with PathAI's AISight Dx digital pathology image management system one of the latest. Medtech Insight talks to Eric Walk, chief medical officer, to find out about the process and its benefits.